Skip to main
ACET

ACET Stock Forecast & Price Target

ACET Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adicet Bio Inc is positioned favorably in the biotechnology sector due to its innovative approach to developing allogeneic gamma delta T cell therapies, particularly with its product candidate ADI-001, which demonstrates promising efficacy and a favorable safety profile compared to traditional autologous CAR-T therapies. The anticipated upcoming clinical readout and initiation of further studies in 2026 are expected to provide significant catalysts for the company's growth. Furthermore, the strategy of utilizing third-party manufacturers for large-scale production helps mitigate manufacturing risks, enhancing the overall viability of Adicet's offerings and bolstering its competitiveness in the marketplace.

Bears say

Adicet Bio Inc faces a negative financial outlook primarily due to projected net losses, with expectations of a $1.13 per share loss for 2025, signaling ongoing financial strain. The company grapples with significant risks, including the potential for lower efficacy of its lead candidate, ADI-001, in patients previously treated with anti-CD20 therapies, and heightened competition could further erode projected market share and revenue generation. Compounding these concerns, the lowered probability of success for ADI-001 in critical indications and increased regulatory risks from unapproved gamma-delta T-cell therapies contribute to skepticism regarding the company's growth prospects and overall financial stability.

ACET has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adicet Bio, Inc. (ACET) Forecast

Analysts have given ACET a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACET has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adicet Bio, Inc. (ACET)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.